TD Cowen Reiterates Buy Rating on Zoetis Inc. (ZTS)

TD Cowen analyst Steve Scala reiterated a Buy rating and $214.00 price target on Zoetis Inc. (NYSE: ZTS).

The analyst commented, "Trends in the animal health market remain compelling, but there are near-term headwinds including depressed vet visits, macroeconomic concerns, and imminent competitor launches. Still, ZTS is well positioned as a leader in the Animal Health market with a solid outlook for top- and bottom-line growth supported by U.S. launches for Librela/Solensia and continued leadership in derm/parasiticides."

For an analyst ratings summary and ratings history on Zoetis Inc. click here. For more ratings news on Zoetis Inc. click here.

Shares of Zoetis Inc. closed at $190.03 yesterday.

You May Also Be Interested In

• Freedom Broker Downgrades Flexsteel (FLXS) to Hold
• AXIL Brands (AXIL) Tops Q4 EPS by 4c
• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform